Health & bio
FDA clears orforglipron on April 1—first oral small-molecule GLP-1
Eli Lilly's orforglipron earned FDA approval April 1. Once-daily oral dosing, 0.8mg starting, with a contraindication against combining with other GLP-1s. First small-molecule GLP-1 agonist for chronic weight management.
Primary sources · 2